NEW YORK (GenomeWeb News) – Bristol-Myers Squibb has renewed its license for Ingenuity Systems’ pathway analysis software for use in genomics and proteomics research aimed at advancing its drug discovery programs, Ingenuity said today.
 
Under the agreement, Bristol-Myers Squibb gains enterprise-wide access to the Ingenuity Pathways Analysis software for modeling, visualization, and interpretation of genomics and proteomics data. BMS has been an Ingenuity customer since 2004.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.